Absorption & Elimination of Radiolabelled GSK2269557

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

[14C]-GSK2269557 IV infusion

The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.

DRUG

GSK2269557 via DPI

GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.

DRUG

[14C]-GSK2269557 oral solution

The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03315559 - Absorption & Elimination of Radiolabelled GSK2269557 | Biotech Hunter | Biotech Hunter